Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00005104
Recruitment Status : Completed
First Posted : April 7, 2000
Last Update Posted : June 24, 2005
University of Virginia
Information provided by:
National Center for Research Resources (NCRR)

April 6, 2000
April 7, 2000
June 24, 2005
January 2000
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome
Not Provided


I. Determine whether reduction of serum insulin levels by metformin increases ovulatory response to clomiphene citrate in women with polycystic ovary syndrome.

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients are randomized to one of two treatment arms.

Patients receive oral metformin or oral placebo three times daily for 7 weeks. Patients remaining anovulatory by day 49 receive metformin or placebo plus escalating doses of oral clomiphene citrate daily for 5 consecutive days, beginning on days 50, 80, and 110. Following ovulation, treatment with clomiphene citrate and metformin or placebo continues until 6 ovulatory cycles occur, pregnancy occurs, or anovulation persists. Patients receiving the placebo arm who have not ovulated on the highest dose of clomiphene citrate may be crossed over to receive metformin after a 6 week washout.

Not Applicable
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
  • Polycystic Ovary Syndrome
  • Hyperinsulinism
  • Drug: clomiphene citrate
  • Drug: metformin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
Not Provided
Not Provided


--Disease Characteristics--

Patients with chronic anovulation due to polycystic ovary syndrome (PCOS) who have failed clomiphene citrate

Must have oligoovulation and hyperandrogenemia

--Prior/Concurrent Therapy--

Endocrine therapy: At least 2 months since prior clomiphene citrate


  • At least 2 months since prior standard therapy (including over the counter drugs)
  • At least 2 months since prior investigational drugs
  • Prior multi/prenatal vitamins allowed

--Patient Characteristics--

Hematopoietic: Hematocrit greater than 38%


  • Liver function normal
  • No clinically significant hepatic disease


  • No clinically significant renal disease
  • Creatinine less than 1.4 mg/dL
  • No proteinuria

Cardiovascular: No clinically significant cardiac disease

Pulmonary: No clinically significant pulmonary disease


  • Thyroid function normal
  • Prolactin normal
  • Estradiol normal
  • Fasting 17 alpha-hydroxy progesterone less than 200 ng/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency


  • Not pregnant
  • Negative pregnancy test
  • Male partner must have a normal semen analysis by WHO criteria
  • Must be in acceptable health by interview, medical history, physical exam, and laboratory tests
  • No diabetes mellitus
  • No clinically significant neurologic, psychiatric, infectious, neoplastic, or metabolic disease
  • No clinically significant malignant disease except nonmelanomatous skin cancer
  • At least 1 year since any prior drug abuse or alcoholism
Sexes Eligible for Study: Female
18 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Italy,   United States
Not Provided
Not Provided
Not Provided
Not Provided
National Center for Research Resources (NCRR)
University of Virginia
Study Chair: William S. Evans University of Virginia
National Center for Research Resources (NCRR)
December 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP